摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4,7-二氢咪唑并[4,5-d][1,3]二氮杂卓-8(1H)-酮 | 72079-77-7

中文名称
4,7-二氢咪唑并[4,5-d][1,3]二氮杂卓-8(1H)-酮
中文别名
4,7-二氢-咪唑并[4,5-d][1,3]氮杂平-8(3H)-酮
英文名称
6,7-dihydroimidazo<4,5-d><1,3>diazepin-8(3H)-one
英文别名
6,7-dihydroimidazo[4,5-d][1,3]diazepin-8(3H)-one;6,7-dihydro-3H-imidazo[4,5-d][1,3]diazepin-8-one;1.3-Diazepinon;4,7-Dihydro-3H-imidazo[4,5-d][1,3]diazepin-8-one;4,7-dihydro-1H-imidazo[4,5-d][1,3]diazepin-8-one
4,7-二氢咪唑并[4,5-d][1,3]二氮杂卓-8(1H)-酮化学式
CAS
72079-77-7
化学式
C6H6N4O
mdl
MFCD04972449
分子量
150.14
InChiKey
ASIWDXWEDFFGPK-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    486.0±55.0 °C(Predicted)
  • 密度:
    1.70

计算性质

  • 辛醇/水分配系数(LogP):
    -0.4
  • 重原子数:
    11
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.166
  • 拓扑面积:
    70.1
  • 氢给体数:
    2
  • 氢受体数:
    3

SDS

SDS:680cd37a6c0a69397d005f18c4ccdff4
查看

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量
    • 1
    • 2
    • 3

反应信息

  • 作为反应物:
    描述:
    4,7-二氢咪唑并[4,5-d][1,3]二氮杂卓-8(1H)-酮 在 sodium tetrahydroborate 、 lithium methanolate 、 sodium hydride 作用下, 以 甲醇二氯甲烷N,N-二甲基甲酰胺 为溶剂, 反应 72.5h, 生成 6-(8-hydroxy-7,8-dihydro-4H-imidazo[4,5-d][1,3]diazepin-3-yl)hexyl-methoxyphosphinic acid
    参考文献:
    名称:
    AMP脱氨酶抑制剂。2.初步发现非核苷酸过渡态抑制剂系列。
    摘要:
    描述了一系列可抑制腺苷5'-单磷酸脱氨酶(AMPDA)或腺苷脱氨酶(ADA)的N3取代的甲酰辅酶A糖苷配基类似物。制备这些化合物的关键步骤是(1)用烷基处理6,7-二氢咪唑并[4,5-d] [1,3] diazepin-8(3H)-one(4)的钠盐溴或甲磺酸烷基酯生成N3-烷基化的化合物5和(2)用NaBH(4)还原5。当N 3-取代基包含羧酸部分时,实现了对AMPDA的选择性抑制。例如,具有己酸侧链的化合物7b抑制了具有K(i)=4.2μM的AMPDA和具有K(i)=280μM的ADA。大的亲脂性基团α取代为羧酸盐,提供了适度的效能提高,同时保持了选择性,如α-苄基类似物7j(AMPDA K(i)= 0.41 microM和ADA K(i)> 1000 microM)所示。这些化合物以及本系列论文中描述的其他化合物,是第一种适合测试AMPDA选择性抑制是否可以通过增加损伤部位的局部腺苷
    DOI:
    10.1021/jm990447m
  • 作为产物:
    描述:
    、 、 ditert-butyl 8-oxo-7H-imidazo[4,5-d][1,3]diazepine-3,6-dicarboxylate 在 乙酰氯 作用下, 以 甲醇 为溶剂, 生成 4,7-二氢咪唑并[4,5-d][1,3]二氮杂卓-8(1H)-酮
    参考文献:
    名称:
    [EN] SYNTHESIS AND MANUFACTURE OF PENTOSTATIN AND ITS PRECURSORS, ANALOGS AND DERIVATIVES
    [FR] SYNTHESE ET PRODUCTION DE PENTOSTATINE, PRECURSEURS, ANALOGUES ET DERIVES DE CETTE DERNIERE
    摘要:
    公开号:
    WO2005027838A3
点击查看最新优质反应信息

文献信息

  • Discovery of AMP Mimetics that Exhibit High Inhibitory Potency and Specificity for AMP Deaminase
    作者:Mark D. Erion、Srinivas Rao Kasibhatla、Brett C. Bookser、Paul D. van Poelje、M. Rami Reddy、Harry E. Gruber、James R. Appleman
    DOI:10.1021/ja983153j
    日期:1999.1.1
    The first potent, specific, and cell-penetrable AMP deaminase (AMPDA) inhibitors were discovered through an investigation of 3-substituted 3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol analogues. Inhibition constants for the most potent inhibitors were 105-fold lower than the KM for the substrate AMP. High affinity required the presence of both the 8-hydroxyl and the 3-substituent and is postulated
    通过对 3-取代 3,6,7,8-四氢咪唑并[4,5-d][1,3]diazepin-8-的研究,发现了第一个有效、特异性和细胞可渗透的 AMP 脱氨酶 (AMPDA) 抑制剂ol 类似物。最有效抑制剂的抑制常数比底物 AMP 的 KM 低 105 倍。高亲和力需要 8-羟基和 3-取代基的存在,并且被假定来自于降低结合熵成本并使二氮杂碱基采用模拟过渡态 (TS) 结构的结合构象的协同相互作用. 相对于其他 AMP 结合酶,AMPDA 抑制剂系列的高特异性 (> 105)部分归因于二氮杂碱,它有利于与用于稳定 TS 结构的残基相互作用,并排除通常由 AMP 结合酶用于结合 AMP 的相互作用。相比之下,AMPDA 和腺苷脱氨酶 (ADA) 之间的区别,这两种酶假定稳定类似的 TS 结构......
  • Studies related to the total synthesis of pentostatin: An efficient, regiospecific glycosylation of 6,7-dihydroimidazo[4,5-d][1,2]diazepin-8(3H)-one and related homologs.
    作者:H.D.Hollis Showalter、Sterling R Putt
    DOI:10.1016/s0040-4039(01)81851-7
    日期:1981.1
    A much improved glycosylation procedure for fhe synthesis of pentostatin-like nucleosides is described.
    描述了用于戊抑制素样核苷合成的大大改进的糖基化方法。
  • Synthesis and manufacture of pentostatin and its precursors, analogs and derivatives
    申请人:Phiasivongsa Pasit
    公开号:US20050267056A1
    公开(公告)日:2005-12-01
    Methods and compositions are provided for efficiently preparing and manufacturing pentostatin. Also provided are novel precursors of pentostatin, pentostatin analogs and derivatives. In one aspect of the invention, a method is provided for total chemical synthesis of pentostatin via a route of heterocyclic ring expansion. For example, a heterocyclic pharmaceutical intermediate for drugs such as pentostatin, e.g., the diazepinone precursor, can be obtained efficiently through a ring expansion of an O—C—N functionality in a hypoxanthine or 2′-deoxyinosine derivative. The methods and compositions can also be used to synthesize and manufacture heterocyclic compounds other than pentostatin, especially pharmaceutically important heterocyclic compounds.
    本发明提供了一种高效制备和生产戊糖核苷的方法和组合物。此外,还提供了戊糖核苷的新型前体、戊糖核苷类似物和衍生物。在本发明的一个方面,提供了一种通过杂环环扩展路线对戊糖核苷进行全合成的方法。例如,可以通过对嘌呤嘧啶或2'-去氧肌苷衍生物中的O-C-N官能团进行环扩展,高效地获得用于药物如戊糖核苷的杂环制药中间体,如噻唑环酮前体。这些方法和组合物还可以用于合成和生产除戊糖核苷以外的其他杂环化合物,特别是药物上重要的杂环化合物。
  • METHOD FOR THE SYNTHESIS OF PENTOSTATIN
    申请人:Synbias Pharma AG
    公开号:EP3115461A1
    公开(公告)日:2017-01-11
    The present invention relates to a method for the stereo-selective production of pentostatin comprising an enzymatic transglycosylation reaction between an imidazo-[4,5-d]-[1,3]diazepine compound and a 2'-deoxyribonucleotide, followed by an ruthenium-catalyzed asymmetric transfer hydrogenation.
    本发明涉及一种立体选择性生产五糖核苷的方法,包括一种咪唑-[4,5-d]-[1,3]二氮杂环化合物和2'-脱氧核苷酸之间的酶促转糖基化反应,随后进行一种铑催化的不对称转移氢化反应。
  • AMP Deaminase Inhibitors. 3. SAR of 3-(Carboxyarylalkyl)coformycin Aglycon Analogues
    作者:Srinivas Rao Kasibhatla、Brett C. Bookser、Gary Probst、James R. Appleman、Mark D. Erion
    DOI:10.1021/jm990448e
    日期:2000.4.1
    N3-Substituted coformycin aglycon analogues with improved AMP deaminase (AMPDA) inhibitory potency are described. Replacement of the 5-carboxypentyl substituent in the lead AMPDA inhibitor 3-(5-carboxypentyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol (2) described in the previous article with various carboxyarylalkyl groups resulted in compounds with 10-100-fold improved AMPDA inhibitory potencies. The optimal N3 substituent had m-carboxyphenyl with a two-carbon alkyl tether. For example, 3-[2-(3-carboxy-5-ethylphenyl)-ethyl]-3,6,7,8-tetrahydroimidazo[4,5-d] [1,3]diazepin-8-ol (43g) inhibited human AMPDA with a K-i = 0.06 mu M. The compounds within the series also exhibited >1000-fold specificity for AMPDA relative to adenosine deaminase.
查看更多

同类化合物

脱氧助间型霉素 化合物RK-33 8-叔-丁基1-乙基6,7-二氢-5H-咪唑并[1,5-A][1,4]二氮杂卓-1,8(9H)-二甲酸基酯 8-(叔丁氧羰基)-6,7,8,9-四氢-5H-咪唑并[1,5-A][1,4]二氮杂-1-羧酸 6-羟基-4,5,6,7-四氢咪唑并[4,5-e][1,4]二氮杂卓-8(1H)-酮 5-(8-羟基-7,8-二氢-4H-咪唑并[5,4-d][1,3]二氮杂卓-3-基)-3-(羟基甲基)环戊-3-烯-1,2-二醇 4,7-二氢咪唑并[4,5-d][1,3]二氮杂卓-8(1H)-酮 3-[(2-羟基乙氧基)甲基]-3,4,7,8-四氢咪唑并[4,5-d][1,3]二氮杂卓-8-醇 1H-咪唑并[1,5-d〕〔1,4]二氮杂(9CI) 1,4,6,7-四氢咪唑并[4,5-e][1,4]二氮杂卓-5,8-二酮 (9ci)-1H-咪唑并[1,2-a][1,4]二氮杂卓 5-methylthio-11H-imidazo[1,2-c][1,3]benzodiazepine 2-methoxy-1,4,7-trimethyl-4,5,7,8-tetrahydro-6H-imidazo<4,5-e><1,4>diazepine-5,8-dione 1-benzyl-5,7-diphenyl-4,5,7,8-tetrahydroimidazo<4,5-e><1,3>diazepin-6-one 6-amino-4,5-dihydro-8H-imidazo[4,5-e][1,3]diazepine-4,8-dione [3-(2-Deoxy-β-D-erythro-pentofuranosyl)-3,6,7,8 tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol]-5'-phosphoric Acid-(3-dodecylmercapto-2-decyloxy)-propyl Ester (4S)-4-benzyl-2-(2,5-dihydroxyphenyl)-3,4-dihydro-5H-pyrido[1',2':1,2]imidazo-[4,5-d][1,3]diazepin-5-one (4S)-4-benzyl-2-(2,5-dimethoxyphenyl)-3,4-dihydro-5H-pyrido[10,20:1,2]imidazo [4,5-d][1,3]diazepin-5-one (4S)-4-methyl-2-(1-naphthyl)-3,4-dihydro-5H-pyrido[1',2':1,2]imidazo-[4,5-d][1,3]diazepin-5-one 6-amino-1-(2'-deoxy-β-D-erythropentofuranosyl)-4,5-dihydro-8H-imidazo[4,5-e][1,3]diazepine-4,8-dione 6-amino-1-(2'-deoxy-α-D-erythropentofuranosyl)-4,5-dihydro-8H-imidazo[4,5-e][1,3]diazepine-4,8-dione (4S)-4-methyl-2-(4-acetamidophenyl)-3,4-dihydro-5H-pyrido[1',2':1,2]imidazo-[4,5-d][1,3]diazepin-5-one 5-(4-methyl-1-piperazinyl)-11H-imidazo[1,2-c][1,3]benzodiazepine monomaleate (8R)-3-[(4R,5S)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7,8-dihydro-4H-imidazo[4,5-d][1,3]diazepin-8-ol (R)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol 6-(decylamino)-1-[(2S,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7H-imidazo[4,5-e][1,3]diazepine-4,8-dione (13S)-11-(4-methoxyphenyl)-13-methyl-2,8,10,12-tetrazatricyclo[7.5.0.02,7]tetradeca-1(9),3,5,7,11-pentaen-14-one (8R)-3-[(2S,4S,5S)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7,8-dihydro-4H-imidazo[4,5-d][1,3]diazepin-8-ol 8-Ketodeoxycoformycin 2'-chloropentostatin CO-Vidarabine (8R)-3-[(1S,2R,4R)-2-(benzoyloxymethyl)-1-benzoyloxycyclopent-4-yl]-8-[(tert-butyldimethylsilyl)oxy]-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepine (8R)-3-Benzyl-6-(tert-butoxycarbonyl)-8-<(tert-butyldimethylsilyl)oxy>-3,6,7,8-tetrahydroimidazo<4,5-d><1,3>diazepine (8R)-3-(2'-Cyanoethyl)-8-<(tert-butyldimethylsilyl)oxy>-3,6,7,8-tetrahydroimidazo<4,5-d><1,3>diazepine 4-propyl-4,5,7,8-tetrahydro-6H-imidazo<4,5-e><1,4>diazepine-5,8-dione 1-benzyl-4-propyl-4,5,7,8-tetrahydro-6H-imidazo<4,5-e><1,4>diazepine-5,8-dione 4-isobutyl-7-methyl-4,5,7,8-tetrahydro-6H-imidazo<4,5-e><1,4>diazepine-5,8-dione 1-benzyl-4,7-diethyl-4,5,7,8-tetrahydro-6H-imidazo<4,5-e><1,4>diazepine-5,8-dione 1-benzyl-4-isobutyl-7-methyl-4,5,7,8-tetrahydro-6H-imidazo<4,5-e><1,4>diazepine-5,8-dione 4,6-diamino-6-(ethylimino)-1,6-dihydroimidazo[4,5-e][1,3]diazepine 4,5-dihydro-8H-6-(N-hexadecyl)amino-1-(2'-deoxy-α-D-erythropentofuranosyl)imidazo[4,5-e]diazepine-4,8-dione 4,5-dihydro-8H-6-(N-tetradecyl)amino-1-(2'-deoxy-α-D-erythropentofuranosyl)imidazo[4,5-e]diazepine-4,8-dione 4,5-dihydro-8H-6-(N-octadecyl)amino-1-(2-deoxy-α-D-erythropentofuranosyl)imidazo[4,5-e]diazepine-4,8-dione 4,6-diamino-6-(octadecylimino)-1,6-dihydroimidazo[4,5-e][1,3]diazepine 8-Imino-2,4-dimethyl-7-phenyl-7,8-dihydro-4H-1,2a,4,5,7-pentaaza-cyclopenta[cd]azulene-3,6-dione 1,4-dimethyl-4,5,7,8-tetrahydro-6H-imidazo<4,5-e><1,4>diazepine-5,8-dione 11H-imidazo[1,2-c][1,3]benzodiazepine-5(6H)-thione (8R)-3-[(4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7,8-dihydro-4H-imidazo[4,5-d][1,3]diazepin-8-ol 2-(4-Chloro-benzylcarbamoyl)-6-(8-hydroxy-7,8-dihydro-6H-imidazo[4,5-d][1,3]diazepin-3-yl)-hexanoic acid benzyl ester (13S)-13-(1H-indol-3-ylmethyl)-2,8,10,12-tetrazatricyclo[7.5.0.02,7]tetradeca-1(9),3,5,7-tetraene-11,14-dione